Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001193125-26-004799 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-02 | INKT | Buell Jennifer | CEO | A - Grant | $11.12 | +31.5K | 68.0K | +86% | +$350.0K |
| D | 2026-01-06 | 2026-01-02 | INKT | Buell Jennifer | CEO | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 31,474 | $11.12 | 67,966 | D | — | — | (F1) Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026. (F2) $11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | A | A | 50,000 | $0.00 | 50,000 | D | $11.12 · — to 2036-01-02 | 50,000 Common Stock | (F3) The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter. |